We have 4 of 18 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
The adaptive response to KRASG12C inhibitors (KRASi) in KRASG12C-mutant lung adenocarcinoma models is profile using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform.
Mutational activation of the KRAS oncogene occurs in over 90% of pancreatic ductal adenocarcinoma (PDAC) patients, and plays a crucial role in tumor initiation, progression, and tumor maintenance. Historically considered undruggable, there has recently been a surge in efforts to develop and improve drugs that target...
Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
